Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
MOUNTAIN VIEW, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conf...
MOUNTAIN VIEW, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in three upcoming investor conferences: ...
ABNB, AQN, COHR, CRCT, DDS, DIS, FFIN, FIGS, GLOB, IGMS, PAGS, PVG, RKT, RSI, SEER, VIAV, WISH, ZIP For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close
– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – Expansion of IgM Platform into Infectious Diseases – MOUNTAIN VIEW, Calif., Aug. ...
Gainers: ERYTECH Pharma (NASDAQ:ERYP) +64%. Allied Healthcare Products (NASDAQ:AHPI) +49%. iFresh (NASDAQ:IFMK) +35%. Marin Software Incorporated (NASDAQ:MRIN) +29%. Atlassian Corporation (NASDAQ:TEAM) +24%. Xiaobai Maimai (NASDAQ:HX) +18%. First High-School Education (NYSE:FHS) +16%. Bridgel...
IGM Biosciences (NASDAQ:IGMS) has appointed Chris H. Takimoto as the company’s new chief medical officer, effective July 29. A veteran in the industry for 30 years in cancer research and development, Takimoto previously served as Senior Vice President, Oncology at Gilead Sciences....
MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chi...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Gainers: Ra Medical Systems (RMED) +25%, Sundial Growers (SNDL) +24%, Kindred Biosciences (KIN) +14%, Lannett (LCI) +11%, IGM Biosciences IGMS +11%.Losers: PetMed Express (PETS) -25%, SELLAS Life Sciences (SLS) -15%, Replimune REPL ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...